Literature DB >> 8994107

Glucose metabolism in the cortical and subcortical brain structures in multiple system atrophy and Parkinson's disease: a positron emission tomographic study.

M Otsuka1, Y Ichiya, Y Kuwabara, S Hosokawa, M Sasaki, T Yoshida, T Fukumura, M Kato, K Masuda.   

Abstract

The brain glucose metabolism was studied by PET with 18F-FDG in 11 patients with multiple system atrophy (MSA) and 12 patients with idiopathic Parkinson's disease (PD). Seven of the 11 MSA patients were diagnosed as having olivopontocerebellar atrophy, two had striatonigral degeneration, while two demonstrated Shy-Drager syndrome. The glucose metabolic rates for each region in the PD patients showed no difference from the normal controls. The frontal, temporal and parietal cortical glucose metabolic rates and the caudate, the putaminal, the cerebellar and the brainstem glucose metabolic rates in the MSA patients decreased significantly from the controls. The atrophy of the cerebellum and the brainstem in the MSA patients were scored by MRI. The cerebellar and brainstem glucose metabolism in the MSA patients decreased as the atrophy score in such regions advanced in each group; however, some patients with no atrophy showed a decreased glucose metabolism. Although the cerebellar and the brainstem glucose metabolism decreased in all MSA patients, such a decrease was not observed in the SND patients. The decrease in the glucose metabolism for the non-cortical regions in the MSA patients seems to be due to a diffuse depletion of the neurons not restricted to the nigrostriatal neurons. Deafferentation to the cerebral cortices seems to result in a decreased cortical metabolism. The differences in the glucose metabolism between MSA and PD as assessed by PET may be caused by the pathophysiological differences between MSA and PD, and such differences therefore appear to be useful when making a differential diagnosis between MSA and PD. The relative sparing of the brainstem and cerebellar glucose metabolism is considered to be a feature of patients with SND.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8994107     DOI: 10.1016/s0022-510x(96)00172-4

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  11 in total

Review 1.  PET/CT in diagnosis of movement disorders.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

2.  A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism (Niccolini and Politis, 2016) : Reply to Jean-Claude Baron Letter to Editor.

Authors:  Marios Politis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03       Impact factor: 9.236

Review 3.  Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group.

Authors:  Iva Stankovic; Florian Krismer; Aleksandar Jesic; Angelo Antonini; Thomas Benke; Richard G Brown; David J Burn; Janice L Holton; Horacio Kaufmann; Vladimir S Kostic; Helen Ling; Wassilios G Meissner; Werner Poewe; Marija Semnic; Klaus Seppi; Atsushi Takeda; Daniel Weintraub; Gregor K Wenning
Journal:  Mov Disord       Date:  2014-04-18       Impact factor: 10.338

Review 4.  Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease.

Authors:  Yilong Ma; David Eidelberg
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.488

Review 5.  Neuroimaging and therapeutics in movement disorders.

Authors:  Thomas Eckert; David Eidelberg
Journal:  NeuroRx       Date:  2005-04

6.  The Legacy of the TTASAAN Report - Premature Conclusions and Forgotten Promises About SPECT Neuroimaging: A Review of Policy and Practice Part II.

Authors:  Dan G Pavel; Theodore A Henderson; Simon DeBruin; Philip F Cohen
Journal:  Front Neurol       Date:  2022-05-17       Impact factor: 4.086

7.  Upregulation of a small vault RNA (svtRNA2-1a) is an early event in Parkinson disease and induces neuronal dysfunction.

Authors:  Elena Miñones-Moyano; Marc R Friedländer; Joan Pallares; Birgit Kagerbauer; Sílvia Porta; Georgia Escaramís; Isidre Ferrer; Xavier Estivill; Eulàlia Martí
Journal:  RNA Biol       Date:  2013-05-01       Impact factor: 4.652

8.  18F-FDG PET in neurodegenerative Langerhans cell histiocytosis : results and potential interest for an early diagnosis of the disease.

Authors:  Maria-João Ribeiro; Ahmed Idbaih; Caroline Thomas; Philippe Remy; Nadine Martin-Duverneuil; Yves Samson; Jean Donadieu; Khê Hoang-Xuan
Journal:  J Neurol       Date:  2008-01-31       Impact factor: 4.849

Review 9.  A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism.

Authors:  Flavia Niccolini; Marios Politis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-07-28       Impact factor: 9.236

Review 10.  An update on MSA: premotor and non-motor features open a window of opportunities for early diagnosis and intervention.

Authors:  Viorica Chelban; Daniela Catereniuc; Daniela Aftene; Alexandru Gasnas; Ekawat Vichayanrat; Valeria Iodice; Stanislav Groppa; Henry Houlden
Journal:  J Neurol       Date:  2020-05-20       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.